12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Deals

Myriad Genetics, J&J deal

Johnson & Johnson's Janssen Research & Development LLC subsidiary will use Myriad's BRACAnalysis test in an open-label Phase III trial evaluating Yondelis trabectedin plus Doxil doxorubicin and dexamethasone vs. Doxil to treat advanced relapsed epithelial...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >